Application for New Once-Daily Viekira Pak Formulation Accepted by FDA

Article

FDA decision expected in second half of 2016.

FDA decision expected in second half of 2016.

A more convenient formulation of a leading hepatitis C drug may reach the hands of patients at some point next year.

AbbVie announced Wednesday that the FDA accepted its New Drug Application (NDA) for a once-daily, fixed-dose formulation of Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets). The drug combination is currently administered twice daily with 3 tablets in the morning and another tablet in the evening, which are taken with a meal.

The all-oral, interferon-free treatment was previously approved with or without ribavirin for genotype 1 chronic hepatitis C virus infection, including the treatment of compensated cirrhosis, but not decompensated cirrhosis.

The new formulation of Viekira Pak includes dasabuvir, ombitasvir, paritaprevir and ritonavir tablets taken as 3 oral tablets once daily with a meal, with or without twice-daily ribavirin. The NDA followed data from a pair of bioavailability studies.

"Nearly 1 year after the launch of Viekira Pak, AbbVie is pleased to announce the acceptance of a New Drug Application for a once-daily formulation for the treatment of patients with chronic genotype 1 hepatitis C," said Michael Severino, MD, executive vice president, research and development and chief scientific officer at AbbVie. "This milestone further underscores AbbVie's commitment to offer people living with hepatitis C optimized treatment options."

Related Videos
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
pharmacy | Image Credit: Diego Cervo - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.